<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7462660\results\search\disease\results.xml">
  <result pre=": bold;} span.year {font-family : courier ; font-style : italic;}" exact="Heart" post="Fail RevHeart Fail RevHeart Failure Reviews1382-41471573-7322Springer USNew York pmcid:"/>
  <result pre="courier ; font-style : italic;} Heart Fail RevHeart Fail RevHeart" exact="Failure" post="Reviews1382-41471573-7322Springer USNew York pmcid: 746266010022 doi: 10.1007/s10741-020-10022-4 : Article"/>
  <result pre="6670University of Thessaly, [3], grid.239578.20000 0001 0675 4725Kaufman Center for" exact="Heart Failure" post="and Recovery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic,"/>
  <result pre="of Thessaly, [3], grid.239578.20000 0001 0675 4725Kaufman Center for Heart" exact="Failure" post="and Recovery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic,"/>
  <result pre="4725Kaufman Center for Heart Failure and Recovery, Heart, Vascular, and" exact="Thoracic" post="Institute, Cleveland Clinic, [4], grid.251313.70000 0001 2169 2489Department of"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="(WHO) declaration of COVID-19 as a global pandemic. Abstract Coronavirus" exact="disease" post="2019 (COVID-19) is due to severe acute respiratory syndrome"/>
  <result pre="pandemic. Abstract Coronavirus disease 2019 (COVID-19) is due to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV)-2 which binds and enters the"/>
  <result pre="Abstract Coronavirus disease 2019 (COVID-19) is due to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV)-2 which binds and enters the host"/>
  <result pre="Coronavirus disease 2019 (COVID-19) is due to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV)-2 which binds and enters the host cells"/>
  <result pre="RAÎ‘Si benefit in patients with several diseases such as hypertension," exact="heart" post="failure, coronary disease, and diabetic kidney disease in the"/>
  <result pre="several diseases such as hypertension, heart failure, coronary disease, and" exact="diabetic kidney disease" post="in the non-COVID-19 era, it is a reasonable strategy"/>
  <result pre="diseases such as hypertension, heart failure, coronary disease, and diabetic" exact="kidney disease" post="in the non-COVID-19 era, it is a reasonable strategy"/>
  <result pre="such as hypertension, heart failure, coronary disease, and diabetic kidney" exact="disease" post="in the non-COVID-19 era, it is a reasonable strategy"/>
  <result pre="until definitive evidence becomes available. Keywords COVID-19 Angiotensin Proinflammatory prolyloligopeptidase" exact="Hypertension" post="Heart failure â€œPrudence is the footprint of Wisdom.â€� â€&quot;"/>
  <result pre="definitive evidence becomes available. Keywords COVID-19 Angiotensin Proinflammatory prolyloligopeptidase Hypertension" exact="Heart" post="failure â€œPrudence is the footprint of Wisdom.â€� â€&quot; Amos"/>
  <result pre="is the footprint of Wisdom.â€� â€&quot; Amos Bronson Alcott Coronavirus" exact="disease" post="2019 (COVID-19) is due to severe acute respiratory syndrome"/>
  <result pre="Bronson Alcott Coronavirus disease 2019 (COVID-19) is due to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV)-2 which binds and enters the"/>
  <result pre="Alcott Coronavirus disease 2019 (COVID-19) is due to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV)-2 which binds and enters the host"/>
  <result pre="Coronavirus disease 2019 (COVID-19) is due to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV)-2 which binds and enters the host cells"/>
  <result pre="system The traditional view is that some of renin-angiotensin system" exact="intermediate" post="products may be processed in alternative ways by ACE2,"/>
  <result pre="coronavirus entry The major entry of SARS-CoV-2 is via the" exact="respiratory" post="system where it readily affects differentiated cells that express"/>
  <result pre="readily affects differentiated cells that express more ACE2 [6]. The" exact="type II" post="transmembrane serine proteases TMPRSS2 and ADAM17 (a disintegrin and"/>
  <result pre="disintegrin and metalloproteinase) promote SARS-CoV entry by ACE2 cleavage, promotes" exact="viral" post="uptake, and SARS-S cleavage, resulting in activation of the"/>
  <result pre="viral uptake, and SARS-S cleavage, resulting in activation of the" exact="viral" post="S protein, which in turn fuses with cell membrane"/>
  <result pre="mechanisms. The precise relationship, however, between ACE2 levels and activity," exact="viral" post="infectivity, and severity of infection, is incompletely understood. ACE2"/>
  <result pre="pandemic, it was suggested that ACE2 dysregulation is implicated in" exact="acute" post="inflammatory lung injury (ILI) by inducing an imbalance in"/>
  <result pre="an imbalance in the RAS. It was proposed that in" exact="acute" post="ILI: (i) a decrease in pulmonary ACE2 and an"/>
  <result pre="was proposed that in acute ILI: (i) a decrease in" exact="pulmonary" post="ACE2 and an increase in ANG II levels occur;"/>
  <result pre="II improves outcomes; and (iii) a lack or decrease of" exact="pulmonary" post="ACE2 aggravates viral-induced ILI [8]. However, these findings are"/>
  <result pre="related to COVID-19 where ACE2 serves as the receptor for" exact="viral" post="entry [13]. The expression of ACE2, SARS-CoV spike (S)"/>
  <result pre="lungs and other organs, indicating that ACE2-expressing cells are the" exact="primary" post="targets for SARS-CoV infection in vivo in humans. High"/>
  <result pre="indicating that ACE2-expressing cells are the primary targets for SARS-CoV" exact="infection" post="in vivo in humans. High levels of PICs were"/>
  <result pre="mortality in COVID-19 [15]. Moreover, obesity, which is associated with" exact="chronic" post="inflammation and high expression of ACE2, significantly increases the"/>
  <result pre="these medicines on the risk of becoming infected with severe" exact="acute" post="respiratory syndrome coronavirus 2 (the virus causing COVID-19) and"/>
  <result pre="medicines on the risk of becoming infected with severe acute" exact="respiratory" post="syndrome coronavirus 2 (the virus causing COVID-19) and do"/>
  <result pre="on the risk of becoming infected with severe acute respiratory" exact="syndrome" post="coronavirus 2 (the virus causing COVID-19) and do not"/>
  <result pre="treatment. 3. Felice C, et al. doi: 10.1093/ajh/hpaa096. Association between" exact="chronic" post="use of ACEi or ARB and COVID-19 outcomes in"/>
  <result pre="and COVID-19 outcomes in hypertensives. 133 COVID-19 hypertensives admitted with" exact="acute" post="respiratory symptoms and/or fever. RAASi do not negatively affect"/>
  <result pre="COVID-19 outcomes in hypertensives. 133 COVID-19 hypertensives admitted with acute" exact="respiratory" post="symptoms and/or fever. RAASi do not negatively affect clinical"/>
  <result pre="Gao C, et al. doi: 10.1093/eurheartj/ehaa433. Association between treatment of" exact="hypertension" post="and mortality of patients with COVID-19. 2877 hospitalized COVID-19"/>
  <result pre="mitigate the risk; and (iii) will RAASi affect risk of" exact="infection" post="when equally exposed to the virus? 5. Gnavi R,"/>
  <result pre="diseases/diabetes (CDD). 316 HY and 171 CDD cases of COVID-19" exact="infection" post="matched with 1580 and 855 controls. No reason to"/>
  <result pre="and 855 controls. No reason to modify antihypertensive therapy. Study" exact="limited" post="to explore whether RAAS therapy increases the risk of"/>
  <result pre="to explore whether RAAS therapy increases the risk of SARS-CoV-2" exact="infection" post="Small sample size 6. Guo T, et al. doi:"/>
  <result pre="patients with COVID-19 than controls attributed to higher prevalence of" exact="cardiovascular disease." post="ACEi/ARB did not affect the risk of COVID-19. Information"/>
  <result pre="not affect the risk of COVID-19. Information on drug use" exact="limited" post="to prescriptions, and actual drug consumption by the case"/>
  <result pre="Information on drug use limited to prescriptions, and actual drug" exact="consumption" post="by the case patients and controls was not assessed."/>
  <result pre="and sex-specific prevalence of COVID-19 and its prognostic factors. 2653" exact="symptomatic" post="patients who tested positive for SARS-CoV. Deeper understanding of"/>
  <result pre="positive for SARS-CoV. Deeper understanding of causal chain from infection," exact="disease" post="onset, and immune response to outcomes. Preprint Association between"/>
  <result pre="outcomes. Preprint Association between ACEi and hospitalization, likely due to" exact="residual" post="confounding. 17. Tedeschi S, et al. doi: 10.1093/cid/ciaa492. Investigation"/>
  <result pre="and whether there is a difference in severity of COVID-19" exact="pneumonia" post="in patients who have taken ACEi/ARB. 274 hospitalized hypertensives"/>
  <result pre="ACEi/ARB was associated with an increased mortality risk. Potential for" exact="residual" post="confounders not considered. Traditional Chinese medicine given in 91%"/>
  <result pre="RASi renin angiotensin system inhibitors, CCBs calcium channel blockers, CVD" exact="cardiovascular disease," post="TnT troponin T Research in the COVID-19 era: the"/>
  <result pre="of hormone therapy [25]. Likewise, beta-blockade therapy in patients with" exact="heart" post="failure (HF) and preserved ejection fraction (HFpEF) reduced mortality"/>
  <result pre="premises: (a) COVID-19 is a pandemic responsible for millions of" exact="infections" post="and hundreds of thousands deaths worldwide; (b) COVID-19 is"/>
  <result pre="in diseases frequently treated with RAASi such as hypertension, other" exact="cardiovascular disease," post="and diabetes; (f) confounding cannot be corrected even after"/>
  <result pre="lacking we must follow the trail to the next best" exact="external" post="evidence and work from there [27]. Based on the"/>
  <result pre="be considered [28, 29]. Guideline-recommended alternatives depend on the underlying" exact="disease" post="and include beta-blockers, which reduce plasma concentrations of ANG"/>
  <result pre="that switching from a RAASi to another antihypertensive therapy in" exact="stable" post="ambulatory patients may occasionally be challenging. However, this challenge"/>
  <result pre="been shown to significantly reduce atherosclerotic events, hospitalization for HF," exact="cardiovascular" post="and total mortality, and progression of chronic kidney disease"/>
  <result pre="to significantly reduce atherosclerotic events, hospitalization for HF, cardiovascular and" exact="total" post="mortality, and progression of chronic kidney disease (CKD) even"/>
  <result pre="hospitalization for HF, cardiovascular and total mortality, and progression of" exact="chronic" post="kidney disease (CKD) even in patients without diabetes [32]."/>
  <result pre="for HF, cardiovascular and total mortality, and progression of chronic" exact="kidney disease" post="(CKD) even in patients without diabetes [32]. Increasing experimental"/>
  <result pre="HF, cardiovascular and total mortality, and progression of chronic kidney" exact="disease" post="(CKD) even in patients without diabetes [32]. Increasing experimental"/>
  <result pre="progression of chronic kidney disease (CKD) even in patients without" exact="diabetes" post="[32]. Increasing experimental and clinical data demonstrated a reduction"/>
  <result pre="these agents, including in key target organs such as the" exact="heart" post="and the kidneys [32]. Fig. 1 Rational and algorithm"/>
  <result pre="the use of renin-angiotensin-aldosterone system (RAAS) inhibitors in the coronavirus" exact="disease" post="2019 (COVID-19) era. It should be noted that this"/>
  <result pre="in COVID-19. The important issue that the outcome of a" exact="viral infection" post="may be related to therapy provided for another underlying"/>
  <result pre="COVID-19. The important issue that the outcome of a viral" exact="infection" post="may be related to therapy provided for another underlying"/>
  <result pre="infection may be related to therapy provided for another underlying" exact="disease" post="should be taken into consideration not only for COVID-19"/>
  <result pre="into consideration not only for COVID-19 but for other future" exact="viral" post="or non-viral infections as well. In the meantime, it"/>
  <result pre="only for COVID-19 but for other future viral or non-viral" exact="infections" post="as well. In the meantime, it is important to"/>
  <result pre="guidelines should be strongly encouraged when there are no alternatives." exact="Deviation" post="from these practices until solid evidence becomes available should"/>
  <result pre="RAÎ‘Si benefit in patients with several diseases such as hypertension," exact="heart" post="failure, coronary disease, and diabetic kidney disease in the"/>
  <result pre="several diseases such as hypertension, heart failure, coronary disease, and" exact="diabetic kidney disease" post="in the non-COVID-19 era, it is a reasonable strategy"/>
  <result pre="diseases such as hypertension, heart failure, coronary disease, and diabetic" exact="kidney disease" post="in the non-COVID-19 era, it is a reasonable strategy"/>
  <result pre="such as hypertension, heart failure, coronary disease, and diabetic kidney" exact="disease" post="in the non-COVID-19 era, it is a reasonable strategy"/>
  <result pre="on their pharmacokinetic and pharmacodynamic effects. The possibility that a" exact="viral infection" post="may alter drug effects and consequently the final disease"/>
  <result pre="their pharmacokinetic and pharmacodynamic effects. The possibility that a viral" exact="infection" post="may alter drug effects and consequently the final disease"/>
  <result pre="viral infection may alter drug effects and consequently the final" exact="disease" post="outcome was not taken into consideration. This is a"/>
  <result pre="from Covia, Amgen, advisory board Medtronic, advisor and steering committee" exact="Cardiac" post="Dimensions, steering committee Novartis. A.X. has received honoraria from"/>
  <result pre="and ZS Pharma. H.B. has no disclosures. References References 1.SommersteinRKochenMMMesserliFHGraniCCoronavirus" exact="disease" post="2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have"/>
  <result pre="2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a" exact="biphasic" post="effect?J Am Heart Assoc202097e01650910.1161/JAHA.120.01650932233753 2.SantosRASSampaioWOAlzamoraACMotta-SantosDAleninaNBaderMCampagnole-SantosMJThe ACE2/angiotensin-(1-7)/MAS axis of the"/>
  <result pre="angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?J Am" exact="Heart" post="Assoc202097e01650910.1161/JAHA.120.01650932233753 2.SantosRASSampaioWOAlzamoraACMotta-SantosDAleninaNBaderMCampagnole-SantosMJThe ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus"/>
  <result pre="Biol201654335936910.1165/rcmb.2015-0108OC26222144 5.BaderMAleninaNYoungDSantosRASTouyzRMThe meaning of MasHypertension20187251072107510.1161/HYPERTENSIONAHA.118.1091830354821 6.JiaHPLookDCShiLHickeyMPeweLNetlandJFarzanMWohlford-LenaneCPerlmanSMcCrayPBJrACE2 receptor expression and severe" exact="acute" post="respiratory syndrome coronavirus infection depend on differentiation of human"/>
  <result pre="5.BaderMAleninaNYoungDSantosRASTouyzRMThe meaning of MasHypertension20187251072107510.1161/HYPERTENSIONAHA.118.1091830354821 6.JiaHPLookDCShiLHickeyMPeweLNetlandJFarzanMWohlford-LenaneCPerlmanSMcCrayPBJrACE2 receptor expression and severe acute" exact="respiratory" post="syndrome coronavirus infection depend on differentiation of human airway"/>
  <result pre="meaning of MasHypertension20187251072107510.1161/HYPERTENSIONAHA.118.1091830354821 6.JiaHPLookDCShiLHickeyMPeweLNetlandJFarzanMWohlford-LenaneCPerlmanSMcCrayPBJrACE2 receptor expression and severe acute respiratory" exact="syndrome" post="coronavirus infection depend on differentiation of human airway epitheliaJ"/>
  <result pre="MasHypertension20187251072107510.1161/HYPERTENSIONAHA.118.1091830354821 6.JiaHPLookDCShiLHickeyMPeweLNetlandJFarzanMWohlford-LenaneCPerlmanSMcCrayPBJrACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epitheliaJ Virol20057923146141462110.1128/JVI.79.23.14614-14621.200516282461 7.HeurichAHofmann-WinklerHGiererSLiepoldTJahnOPohlmannSTMPRSS2"/>
  <result pre="only proteolysis by TMPRSS2 augments entry driven by the severe" exact="acute" post="respiratory syndrome coronavirus spike proteinJ Virol20148821293130710.1128/JVI.02202-1324227843 8.GheblawiMWangKViveirosANguyenQZhongJCTurnerAJRaizadaMKGrantMBOuditGYAngiotensin converting enzyme"/>
  <result pre="proteolysis by TMPRSS2 augments entry driven by the severe acute" exact="respiratory" post="syndrome coronavirus spike proteinJ Virol20148821293130710.1128/JVI.02202-1324227843 8.GheblawiMWangKViveirosANguyenQZhongJCTurnerAJRaizadaMKGrantMBOuditGYAngiotensin converting enzyme 2:"/>
  <result pre="by TMPRSS2 augments entry driven by the severe acute respiratory" exact="syndrome" post="coronavirus spike proteinJ Virol20148821293130710.1128/JVI.02202-1324227843 8.GheblawiMWangKViveirosANguyenQZhongJCTurnerAJRaizadaMKGrantMBOuditGYAngiotensin converting enzyme 2: SARS-CoV-2"/>
  <result pre="angiotensin-converting enzyme 2 and angiotensin-(1-7) bioencapsulated in plant cells attenuates" exact="pulmonary" post="hypertensionHypertension20146461248125910.1161/HYPERTENSIONAHA.114.0387125225206 10.RigattoKCasaliKRShenoyVKatovichMJRaizadaMKDiminazene aceturate improves autonomic modulation in pulmonary hypertensionEur"/>
  <result pre="cells attenuates pulmonary hypertensionHypertension20146461248125910.1161/HYPERTENSIONAHA.114.0387125225206 10.RigattoKCasaliKRShenoyVKatovichMJRaizadaMKDiminazene aceturate improves autonomic modulation in" exact="pulmonary" post="hypertensionEur J Pharmacol20137131â€&quot;3899310.1016/j.ejphar.2013.04.01723665493 11.Rey-ParraGJVadivelAColtanLHallAEatonFSchusterMLoibnerHPenningerJMKassiriZOuditGYThebaudBAngiotensin converting enzyme 2 abrogates bleomycin-induced"/>
  <result pre="lung injuryJ Mol Med (Berl)201290663764710.1007/s00109-012-0859-222246130 12.TremlBNeuNKleinsasserAGritschCFinsterwalderTGeigerRSchusterMJanzekELoibnerHPenningerJLoeckingerARecombinant angiotensin-converting enzyme 2 improves" exact="pulmonary" post="blood flow and oxygenation in lipopolysaccharide-induced lung injury in"/>
  <result pre="in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the" exact="acute" post="lung injury and pathogenesis of SARSJ Pathol2006210328829710.1002/path.206717031779 14.Li G,"/>
  <result pre="in the pathogenesis of COVID-19. J Autoimmun:102463. 10.1016/j.jaut.2020.102463 15.TomasoniDItaliaLAdamoMInciardiRMLombardiCMSolomonSDMetraMCOVID 19" exact="and heart" post="failure: from infection to inflammation and angiotensin II stimulation."/>
  <result pre="the pathogenesis of COVID-19. J Autoimmun:102463. 10.1016/j.jaut.2020.102463 15.TomasoniDItaliaLAdamoMInciardiRMLombardiCMSolomonSDMetraMCOVID 19 and" exact="heart" post="failure: from infection to inflammation and angiotensin II stimulation."/>
  <result pre="COVID-19. J Autoimmun:102463. 10.1016/j.jaut.2020.102463 15.TomasoniDItaliaLAdamoMInciardiRMLombardiCMSolomonSDMetraMCOVID 19 and heart failure: from" exact="infection" post="to inflammation and angiotensin II stimulation. Searching for evidence"/>
  <result pre="II stimulation. Searching for evidence from a new diseaseEur J" exact="Heart" post="Fail20202295796610.1002/ejhf.187132412156 16.KassirRRisk of COVID-19 for patients with obesityObes Rev2020216e1303410.1111/obr.1303432281287"/>
  <result pre="cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental" exact="heart" post="failureAm J Physiol Heart Circ Physiol20052894H1351H135810.1152/ajpheart.01186.200415894569 19.MouradJJLevyBIInteraction between RAAS"/>
  <result pre="enzyme isoforms in rats with experimental heart failureAm J Physiol" exact="Heart" post="Circ Physiol20052894H1351H135810.1152/ajpheart.01186.200415894569 19.MouradJJLevyBIInteraction between RAAS inhibitors and ACE2 in"/>
  <result pre="reservations against contradicted percutaneous coronary intervention indications: citation content analysisAm" exact="Heart" post="J2009157469570110.1016/j.ahj.2008.11.02319332198 24.FanaroffACCaliffRMHarringtonRAGrangerCBMcMurrayJJVPatelMRBhattDLWindeckerSHernandezAFGibsonCMAlexanderJHLopesRDRandomized trials versus common sense and clinical observation:"/>
  <result pre="for comprehensive data collection and outcome assessmentBMJ Open201337e00255610.1136/bmjopen-2013-00255623861441 26.BavishiCChatterjeeSAtherSPatelDMesserliFHBeta-blockers in" exact="heart" post="failure with preserved ejection fraction: a meta-analysisHeart Fail Rev201520219320110.1007/s10741-014-9453-825034701"/>
  <result pre="der MeerP2016 ESC guidelines for the diagnosis and treatment of" exact="acute" post="and chronic heart failureRev Esp Cardiol (Engl Ed)20166912116710.1016/j.rec.2016.11.00527894487 29.WilliamsBManciaGSpieringWAgabiti"/>
  <result pre="ESC guidelines for the diagnosis and treatment of acute and" exact="chronic" post="heart failureRev Esp Cardiol (Engl Ed)20166912116710.1016/j.rec.2016.11.00527894487 29.WilliamsBManciaGSpieringWAgabiti RoseiEAziziMBurnierMClementDLCocaAde SimoneGDominiczakAKahanTMahfoudFRedonJRuilopeLZanchettiAKerinsMKjeldsenSEKreutzRLaurentSLipGYHMcManusRNarkiewiczKRuschitzkaFSchmiederREShlyakhtoETsioufisCAboyansVDesormaisIcollab:"/>
  <result pre="guidelines for the diagnosis and treatment of acute and chronic" exact="heart" post="failureRev Esp Cardiol (Engl Ed)20166912116710.1016/j.rec.2016.11.00527894487 29.WilliamsBManciaGSpieringWAgabiti RoseiEAziziMBurnierMClementDLCocaAde SimoneGDominiczakAKahanTMahfoudFRedonJRuilopeLZanchettiAKerinsMKjeldsenSEKreutzRLaurentSLipGYHMcManusRNarkiewiczKRuschitzkaFSchmiederREShlyakhtoETsioufisCAboyansVDesormaisIcollab: Group"/>
  <result pre="Group ESCSD2018 ESC/ESH guidelines for the management of arterial hypertensionEur" exact="Heart" post="J201839333021310410.1093/eurheartj/ehy33930165516 30.Roca-CusachsAAracil-VilarJCalvo-GomezCVaquer-PerezJVLaporta-CrespoFRojas-SerranoMJGugliettaAGropperScollab: Torasemide PRiHCTIGClinical effects of torasemide prolonged release"/>
  <result pre="torasemide immediate releaseCardiovasc Ther20082629110010.1111/j.1527-3466.2008.00046.x18485132 31.KasamaSToyamaTHatoriTSuminoHKumakuraHTakayamaYIchikawaSSuzukiTKurabayashiMEffects of torasemide on cardiac sympathetic" exact="nerve" post="activity and left ventricular remodelling in patients with congestive"/>
  <result pre="nerve activity and left ventricular remodelling in patients with congestive" exact="heart" post="failureHeart200692101434144010.1136/hrt.2005.07976416621879 32.ZelnikerTABraunwaldEMechanisms of cardiorenal effects of sodium-glucose cotransporter 2"/>
 </snippets>
</snippetsTree>
